China clamps down on investigator-initiated biotech trials after patient deaths, halting rare-disease studies

Chinese regulators have introduced new rules that sharply limit investigator‑initiated biotech trials after a series of patient deaths were reported this summer. The policy shift is intended to tighten oversight of experimental therapies that have been run with relatively little government supervision.

The crackdown hits families of children with rare genetic diseases hardest. One mother recounts how her 13‑year‑old daughter was diagnosed only after a two‑year search that included travel to the United States, and how a local foundation had helped bring affordable genetic‑treatment trials to China. Those trials were poised to expand before the new restrictions took effect.

Investors, particularly those from the United States, now face an uncertain landscape as two pending trials were put on hold and the approval process for future investigator‑initiated studies entered a “shakedown” phase. The stricter environment could slow the development of rare‑disease therapies in China for the foreseeable future.